Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein responseShow others and affiliations
2018 (English)In: Pharmacology and Therapeutics, ISSN 0163-7258, E-ISSN 1879-016X, Vol. 184, p. 13-41Article, review/survey (Refereed) Published
Abstract [en]
Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB.
Place, publisher, year, edition, pages
PERGAMON-ELSEVIER SCIENCE LTD , 2018. Vol. 184, p. 13-41
Keywords [en]
Cell death; Apoptosis; Autophagy; Unfolded protein response; Brain tumor; Glioblastoma; Glioblastoma stem cells; DNA repair; Bcl-2 family protein; Cancer therapy; Temozolomide; Alkylating drugs
National Category
Biomedical Laboratory Science/Technology
Identifiers
URN: urn:nbn:se:liu:diva-147578DOI: 10.1016/j.pharmthera.2017.10.017ISI: 000429504300002PubMedID: 29080702OAI: oai:DiVA.org:liu-147578DiVA, id: diva2:1201829
Note
Funding Agencies|Health Science Foundation [46602]; Mitacs [FR18469]; University Collaborative Research Program [47144]; Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation (CFI); Cancer Research Society (CRS); Research Manitoba; Department of Surgery Research Fund
2018-04-262018-04-262018-04-26